Educating health professionals about drug and device promotion: Advocates' recommendations

PLoS Medicine

Volumn 3, Issue 11, 2006, Pages 1988-1991

  Mansfield, Peter R ^a,b   Lexchin, Joel ^c   Wen, Leana S ^h   Grandori, Luisella ^d   McCoy, Christopher P ^h   Hoffman, Jerome R ^e   Ramos, Joana ^f   Jureidini, Jon N ^a,g  

^a Healthy Skepticism Inc   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c YORK UNIVERSITY   (Canada)

^d Healthy Skepticism Inc   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Cancer Resources and Advocacy   (United States)

^g WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB; SEX HORMONE; DRUG;

ADVERTIZING; BREAST CANCER; CLINICAL RESEARCH; CONTINUING EDUCATION; CORONARY ARTERY DISEASE; DRUG MARKETING; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH PRACTITIONER; HOSPITAL POLICY; HUMAN; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL SOCIETY; MEDICAL STUDENT; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; ARTICLE; DEVICES; EDUCATION; HEALTH CARE PERSONNEL; VOCATIONAL EDUCATION;

ADVERTISING AS TOPIC; EDUCATION, PROFESSIONAL; EQUIPMENT AND SUPPLIES; HEALTH PERSONNEL; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 33845243006     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040451     Document Type: Short Survey

References (40)

1. Almasi EA, Stafford RS, Kravitz RL, Mansfield PR (2006) What are the public health effects of direct-to-consumer drug advertising? PLoS Med 3: e145. doi:10.1371/journal.pmed.0030145
2. Fugh-Berman A, Pearson C (2002) The overselling of hormone replacement therapy. Pharmacotherapy 22: 1205-1208.
3. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 365: 475-481.
4. Mansfield PR (2005) Banning all drug promotion is the best option pending major reforms. J Bioeth Inq 2: 16-22.
5. Accreditation Council for Continuing Medical Education (2002) Principles to guide the relationship between graduate medical education and industry. Chicago: Accreditation Council for Continuing Medical Education. Available: http://www.acgme.org/acWebsite/positionPapers/pp_GMEGuide.pdf. Accessed 22 September 2006.
6. Mintzes B (2005) Educational initiatives for medical and pharmacy students about drug promotion: An international cross-sectional survey. Geneva: World Health Organization and Health Action International. Available: http://www.haiweb.org/26012006/MRhaipromosurveyFINAL06.pdf. Accessed 22 September 2006.
7. Lomas J, Enkin M, Anderson GM, Hannah WJ, Vayda E, et al. (1991) Opinion leaders vs audit and feedback to implement practice guidelines. Delivery after previous cesarean section. JAMA 265: 2202-2207.
8. Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN (2004) The ethics of pharmaceutical industry relationships with med ical students. Med J Aust 180: 411-414.
9. Steinbrook R (2005) Commercial support and continuing medical education. N Engl J Med 352: 534-535.
10. Schafer A (2004) Biomedical conflicts of interest: A defence of the sequestration thesis-learning from the cases of Nancy Olivieri and David Healy. J Med Ethics 30: 8-24.
11. Katz D, Mansfield P, Goodman R, Tiefer L, Merz J (2003) Psychological aspects of gifts from drug companies. JAMA 290: 2404-2405.
12. Brodkey AC (2005) The role of the pharmaceutical industry in teaching psychopharmacology: A growing problem. Acad Psychiatry 29: 222-229.
13. Farthing-Papineau EC, Peak AS (2005) Pharmacists' perceptions of the pharmaceutical industry. Am J Health Syst Pharm 62: 2401-2409.
14. Viale PH (2003) What nurse practitioners should know about direct-to-consumer advertising of prescription medications. J Am Acad Nurse Pract 15: 297-304.
15. Kumar CJ, Deoker A, Kumar A, Kumar A, Hegde BM (2006) Awareness and attitudes about disease mongering among medical and pharmaceutical students. PLoS Med 3: e213. doi:10.1371/journal.pmed.0030213.
16. Grant DC, Iserson KV (2005) Who's buying lunch: Are gifts to surgeons from industry bad for patients? Thorac Surg Clin 15: 533-542.
17. Baron J (2000) Thinking and deciding. 3rd ed. Cambridge: Cambridge University Press. 576 p.
18. Mansfield PR (2003) Healthy Skepticism's new AdWatch: Understanding drug promotion. Med J Aust 179: 644-645.
19. Scott DK, Ferner RE (1994) "The strategy of desire" and rational prescribing. Br J Clin Pharmacol 37: 217-219.
20. Shaughnessy AF, Slawson DC, Bennett JH (1994) Separating the wheat from the chaff: Identifying fallacies in pharmaceutical promotion. J Gen Intern Med 9: 563-568.
21. Cialdini RB (2000) Influence: Science and practice. 4th Ed. New York: Allyn & Bacon. 262 p.
22. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programs. Oxford: Oxford University Press. 305 p.
23. Sackett DL (2001) Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!). CMAJ 165: 1226-1237.
24. Naimark D, Naglie G, Detsky AS (1994) The meaning of life expectancy: What is a clinically significant gain? J Gen Intern Med 9: 702-707.
25. Gilovich T, Griffin D, Kahneman D, editors (2003) Heuristics and biases: The psychology of intuitive judgment. Cambridge: Cambridge University Press. 874 p.
26. Norris P, Herxheimer A, Lexchin J, Mansfield P (2005) Drug promotion: What we know, what we have yet to learn. Geneva: World Health Organization. Available: http://www.who.int/entity/medicines/areas/rational_use/drugPromodhai. pdf. Accessed 22 September 2006.
27. Sagarin BJ, Cialdini RB, Rice WE, Serna SB (2002) Dispelling the illusion of invulnerability: The motivations and mechanisms of resistance to persuasion. J Pers Soc Psychol 83: 526-541.
28. Mansfield P (2004) Accepting what we can learn from advertising's mirror of desire. BMJ 329: 1487-1488.
29. Wilkes MS, Hoffman JR (2001) An innovative approach to educating medical students about pharmaceutical promotion. Acad Med 76: 1271-1277.
30. Sierles FS, Brodkey AC, Cleary LM, McCurdy FA, Mintz M, et al. (2005) Medical students' exposure to and attitudes about drug company interactions: a national survey. JAMA 294: 1034-1042.
31. Mansfield PR, Henry D (2004) Misleading drug promotion-no sign of improvements. Pharmacoepidemiol Drug Saf 13: 797-799.
32. Brody H (2005) The company we keep: Why physicians should refuse to see pharmaceutical representatives. Ann Fam Med 3: 82-85.
33. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, et al. (2006) Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. JAMA 295: 429-433.
34. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS (2001) Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA 286: 1994-1999.
35. Caamano F, Figueiras A, Gestal-Otero JJ (2002) Influence of commercial information on prescription quantity in primary care. Eur J Public Health 12: 187-191.
36. Watkins C, Harvey I, Carthy P, Moore L, Robinson E, et al. (2003) Attitudes and behaviour of general practitioners and their prescribing costs: A national cross sectional survey. Qual Saf Health Care 12: 29-34.
37. Verdoux H, Cougnard A, Grolleau S, Begaud B (2005) Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care. Schizophr Res 77: 107-109.
38. Rosenthal M (2003) Demand effects of recent changes in prescription drug promotion. Menlo Park (California): Kaiser Family Foundation. Available: http://www.kff.org/rxdrugs/upload/Demand-Effects-of-Recent-Changes-in- Prescription-Drug-Promotion-Report.pdf. Accessed 22 September 2006.
39. Shorr RI, Greene WL (1995) A food-borne outbreak of expensive antibiotic use in a community teaching hospital. JAMA 273: 1908.
40. Mansfield P, Rogers W, Jureidini J (2005) Submission from Healthy Skepticism re RACP ethical guidelines. Healthy Skepticism International News 23: 9. Available: http://www.healthyskepticism.org/news/issue.php?id=15. Accessed 22 September 2006.